Common in Later Life and Early Warning of Neurodegenerative Disease
; ; ; ;
Background: Disturbances of smell and taste are common. About 5% of the general population have anosmia (absence of the sense of smell). Olfactory dysfunction can markedly impair the quality of life.
Methods: Review of pertinent literature retrieved by a selective search.
Results: In recent years, simple and reliable tests of the sense of smell have been introduced in otorhinolaryngology. Olfactory testing has become a new focus of attention in neurology as well, mainly because many patients with neurodegenerative diseases—including the majority of those with Parkinson’s or Alzheimer’s disease—have olfactory loss early on in the course of their disorder. Olfactory dysfunction is thus regarded as an early sign of neurodegenerative disease that may allow a tentative diagnosis to be made years before the motor or cognitive disturbances become evident. As for the treatment of olfactory loss, anti-inflammatory drugs and surgery can help in some cases, and olfactory training can lead to significant improvement of post-viral olfactory deficits.
Conclusion: Olfactory dysfunction is common and becomes more common with advancing age. It is increasingly receiving attention as an important sign for the early diagnosis and the differential diagnosis of neurodegenerative disorders.
The sense of smell is particularly important in recognition of danger, in interpersonal communication, and in eating and drinking (1). Most of the complaints of patients who have become anosmic or were born without a sense of smell fall into these three categories:
- The absence of an olfactory warning function often leads to food poisoning.
- The inability to perceive body odors may lead to insecurity in partnerships or in contact with children, for example.
- The pleasure gained from eating and drinking is greatly reduced.
Owing to these limitations many patients with olfactory dysfunction show signs of depression (2).
Interestingly, around 5% of people are anosmic. The loss of olfactory function clearly increases with age: Above 50, a quarter of the population has an impaired sense of smell (presbyosmia) (3–5). Although this is well known, research into olfaction is at least 40 years behind work on the senses of hearing and sight. It was not until 2004, for instance, that a Nobel Prize was awarded for research into the sense of smell. This also goes to show how smell plays a much less important part in human life than hearing and vision.
This article is based essentially on the findings of a selective literature review.
As a rule, olfaction forms one component of a multisensory event. Eating and drinking involves the interaction of at least three sensory pathways: the gustatory, trigeminal, and olfactory systems (6). The gustatory system (glossopharyngeal, facial, and vagus nerves) conveys sweet, sour, salty, bitter, and umami flavors (umami is the flavor of glutamate, best described as the taste of meat broth). The trigeminal nerve transmits sensations such as the pungency of mustard and the sparkling of carbonated drinks. The olfactory system picks up thousands of different odors from the environment via the nostrils, but when food and drink are being consumed the smells reach the olfactory mucosa by way of the throat, imparting the final subtleties of taste. Many patients who have lost their sense of smell initially complain that their sense of taste is blunted.
The olfactory mucosa is situated in the upper third of the nasal cavity; only about 10% of inhaled air reaches the olfactory epithelium (e1).
Odoriferous substances penetrate the mucous membrane and activate the olfactory receptor proteins on the cell wall of the apical cilia of the olfactory cells (7). The special characteristic of the ca. 6 to 30 million olfactory receptor neurons (ORNs) is that they continuously renew themselves from the basal cells. This regeneration capacity diminishes with increasing age (interestingly, there is a statistical association between olfactory acuity and mortality ).
Around 380 functional receptors are coded in the human genome (9, 10). Every ORN expresses a certain receptor type. ORNs that express the same receptor type send axons to specific glomeruli in the olfactory bulb (OB). Odors regularly bind to more than one type of receptor. This leads to various patterns of stimulation in the OB that serve to code the quality of odors. The subsequent cerebral processing of odors involves, among other structures, the limbic system (e.g., amygdala, hippocampus), cerebellum, and insula (11). The orbitofrontal cortex is important for the conscious perception of odors (5).
The most important thing when investigating olfactory dysfunction is to take a detailed medical history. Patients must be asked about the onset, course, and nature of the impairment, their previous illnesses, and the medications they have taken (12). The ENT examination should include nasal endoscopy. Referral to a neurologist is advisable particularly in the case of idiopathic olfactory dysfunction. Magnetic resonance imaging (MRI) of the brain may be necessary, for instance if the dysfunction is suspected to be congenital.
After initial, at least cursory assessment of the sense of taste with flavor sprays, the patient’s sense of smell is investigated. There are simple screening tests that distinguish between “healthy” and “sick,” deliver useful and readily understandable results in a matter of minutes, and are easy to apply. The Olfactology/Gustology Working Group of the German Society of Otorhinolaryngology, Head and Neck Surgery recommends “Sniffin’ Sticks” for this purpose (Figure 1). The “Sniffin’ Sticks” system comprises a screening test, more extensive tests of the detection and distinction of odors, and determination of the olfactory threshold. The pen-like devices containing the odoriferous substances are reusable (13). In the case of more complex problems, additional information can be provided by retronasal tests of olfaction, recording of olfactory evoked potentials, and volume measurement of the OB (13).
Olfactory dysfunction is divided into quantitative and qualitative impairments (Table 1). The principal causes of olfactory dysfunction include:
- Viral infections
- Rhinosinusitis or nasal polyposis
- Neurodegenerative illnesses such as Parkinson disease or Alzheimer dementia (14, 15).
Posttraumatic olfactory dysfunction may be due to rupture of the olfactory filaments or cerebral contusion. In the case of viral infections, the causal factor is assumed to be damage to the ORNs. The causes of sinonasal olfactory dysfunction include inflammatory or mechanical factors such as diversion of access to the olfactory epithelium (13). Smell tests can contribute to the localization of the underlying pathology. If only the ability to discriminate between odors is affected, central nervous impairment can be suspected, while isolated shifting of the olfactory threshold tends to indicate peripheral damage (16).
Early symptom of neurodegenerative disease
In recent years, extensive investigations have confirmed the association between neurodegenerative disease and olfactory impairment and demonstrated the high diagnostic significance of this link (17–19). Olfactory dysfunction thus serves as an early warning of the most frequent neurodegenerative diseases —idiopathic Parkinson disease (IPD) and Alzheimer dementia (AD)—and aids differential diagnosis.
Idiopathic Parkinson disease
Together with tremor, rigidity, and akinesia, olfactory dysfunction is a prominent symptom of IPD (17). Taking the olfactory function of healthy young people as the normal value, over 95% of patients with IPD exhibit olfactory impairment (20) (Figure 2). Even using age-related normal values (21), almost 75% of IPD patients have hyposmia or functional anosmia. The test (21) shows severe hyposmia or anosmia in most patients, occasionally accompanied by parosmia. The olfactory deficit can be detected by simple means, but comprehensive olfactory testing offers the greatest sensitivity. In patients found to have normal olfactory function the diagnosis of IPD should be reconfirmed or other diagnoses considered.
At the individual level it is very difficult to establish a correlation between the extent of olfactory impairment and the duration of the Parkinson disease symptoms. However, measurement of evoked potentials (EPs) after passive olfactory stimulation demonstrated a correlation between EP latency times and the severity of IPD (22). Furthermore, a recently published study indicates a marker function for hyposmia for disease progression, at least in the early stages (23).
Olfactory dysfunction is an early symptom of IPD. Because the sense of smell deteriorates only slowly, however, the loss of olfactory acuity often goes unnoticed by those affected and is hardly ever reported. The olfactory impairment is thought to precede the motor symptoms by ca. 4 to 6 years. For this reason IPD should be considered in at least some cases of idiopathic olfactory dysfunction, particularly in patients who display REM sleep behavior disorder or depression. In a study of 361 relatives of IPD patients who themselves showed no motor symptoms, 4 (10 %) of the 40 subjects found to have hyposmia were diagnosed as having IPD 2 years later (24) (see ). These findings receive support from the model described by Braak et al. (26), according to which the earliest pathological changes in stage I occur in the OB and the anterior olfactory nucleus, while the substantia nigra is not involved until stage III. These early changes in olfactory function currently form part of several longitudinal cohort studies (e.g., www.trend-studie.de).
Other parkinsonian syndromes
Severe olfactory dysfunction is also found in Lewy body dementia. The olfactory impairment is less far-reaching in multisystemic atrophy, and patients with progressive supranuclear ophthalmoplegia (PSP) or corticobasal degeneration (CBD) generally have practically unaffected olfactory function (18). The American Academy of Neurology now recommends including tests of olfaction in the diagnosis of IPD, although so far only the distinction of IPD from PSP or CBD is viewed as reliable.
Very few studies have provided data on olfactory function in familial Parkinson disease. While mild hyposmia was observed in individuals with mutations in the alpha-synuclein gene (PARK-1), persons with mutations in the parkin gene (PARK-2) showed practically normal olfactory function. Individuals with mutations in the LRRK2 gene (PARK-8) displayed olfactory dysfunction identical to that in IPD; however, the small number of asymptomatic carriers of the gene examined to date were normosmic (e2).
Differentiation of vascular Parkinson disease from IPD may be difficult because of the possibly similar findings (27).
Patients with neuroleptic drug–induced parkinsonian syndromes exhibit moderate olfactory dysfunction (28). There is a close correlation between the degree of hyposmia and the severity of the motor symptoms. This raises the question of whether the patients who develop parkinsonism under the influence of neuroleptics possess a predisposition for IPD, or whether the administration of neuroleptics unmasks IPD and the accompanying olfactory dysfunction.
In symptomatic parkinsonian syndromes, e.g. on the basis of Wilson disease, there is a clear correlation between olfactory dysfunction and extrapyramidal motor symptoms. This illustrates the close connection between the function of the basal ganglia and olfactory processing (29).
The olfactory deficits observed in patients with Alzheimer dementia (AD) are similar in severity to those in IPD. Olfactory testing cannot distinguish between early AD and early IPD (30). In AD as in IPD, olfactory dysfunction is an early symptom. According to Braak et al. (31), there is very early involvement of the entorhinal cortex, which plays a role in both mnestic and olfactory processing. In contrast to IPD, therefore, a clear correlation has been demonstrated between the severity of symptoms and olfactory performance. Patients with AD also display MRI signs of OB volume reduction at a very early stage. Patients with only mild cognitive impairments were found to have impaired olfactory function compared with healthy controls (32), and the deterioration in olfactory performance may precede the cognitive deficits.
Similarly severe olfactory abnormalities have been described in other dementias of neurodegenerative origin, such as the above-mentioned Lewy body dementia and frontotemporal dementia.
Huntington disease is associated with moderate hyposmia. Family members with a 50% risk of disease show no olfactory abnormalities (see, for example, [e3]), so it can be assumed that the olfactory changes begin at the same time as the motor and cognitive symptoms. In contrast, Larsson et al. (33) reported odor discrimination impairments in asymptomatic carriers of the Huntington disease gene.
Other neurodegenerative diseases
Many other neurodegenerative diseases are accompanied by olfactory dysfunction, but usually not as an early symptom. Among the heredoataxias, olfactory function has so far been investigated, and impairments found, in patients with Friedreich ataxia and spinocerebellar ataxia types 2 and 3. Mild olfactory dysfunction is also found in motor neuron diseases. Hyposmia has been described as occurring early in the course of Creutzfeldt–Jakob disease; for other prion diseases the data are insufficient. Worthy of mention is a study in knockout mice demonstrating that the physiological prion protein has a role in olfactory processing (34).
Prognosis and treatment
The prognosis of olfactory dysfunction depends on the cause. There is very little that can be done to affect age-related and congenital olfactory dysfunction; the patients can best be helped by counseling (www.hno.org/olfaktologie/index.html [in German]). Ten to thirty percent of patients with posttraumatic anosmia and around 60% of those with postinfectious olfactory dysfunction experience partial recovery over the course of time. Factors that favor recovery from posttraumatic and postinfective impairment of the sense of smell include:
- High residual olfactory capacity
- Young age
- Initial parosmia
- Absence of lateral differences in olfactory function
- Large amplitudes of the chemosensory evoked potentials to trigeminal stimuli
- Large OB volume.
The time since the onset of olfactory dysfunction is also prognostically relevant (35).
Treatment of the cause of olfactory dysfunction is possible only when nasal diseases are responsible (see review in ). Operative treatment, e.g., polypectomy or surgery for pansinusitis, and administration of corticosteroids are the primary options.
The best results in surgical treatment of olfactory dysfunction are generally thought to be obtained in patients with polyposis. The patient’s age and the number of previous operations do not predict postoperative olfactory performance (36).
Corticoids for conservative treatment of sinonasal olfactory dysfunction can be administered topically or systemically (e4). Systemic corticoids are often given in the form of so-called cortisone pulse therapy (e.g., 40 mg initially with reduction by 5 mg every 2 days). This procedure also seems sensible in idiopathic olfactory dysfunction, for instance in the case of endoscopically undetectable mucosal swelling in the olfactory fissure. Because of the nasal filtering function, local corticoids (37) should be given using an extra-long applicator (e5) or with the patient’s head tilted backwards.
With regard to the treatment of other, nonsinonasal forms of olfactory dysfunction, accounts of some interesting approaches have been published but no blinded studies have been conducted. The procedures described include the use of caroverine, alpha-lipoic acid, theophylline, or acupuncture; most of these approaches are based on the hope that the olfactory system will be possessed of plasticity. One newly described approach, olfactory training, takes advantage of the unique regenerative capacity of the ORNs (38). A multicenter double-blind study under the aegis of the Olfactology/Gustology Working Group of the German Society of Otorhinolaryngology, Head and Neck Surgery demonstrated that this inexpensive, complication-free stimulation of the sense of smell in patients with postviral olfactory disorders achieved improvement of olfactory function that was significantly better than spontaneous recovery (manuscript in preparation).
Treatment options in dysfunction of neurodegenerative origin
Medicinal treatment of IPD seems to have no effect on the olfactory dysfunction. In contrast to dopaminergic therapy, deep brain stimulation in the subthalamic nucleus showed a positive effect on some aspects of olfactory processing (e6). One promising approach is the recently described olfactory training (38), in which the patient regularly sniffs at samples of various odors.
Olfactory dysfunction can considerably impair the patient’s quality of life but is not always seen as meriting treatment, partly because attention is focused on the symptoms of the underlying disease and partly owing to the gradual development of the dysfunction in most neurodegenerative diseases, so that patients become accustomed to it. Nevertheless, in view of the potential consequences of olfactory dysfunction, e.g., failing to notice that foodstuffs are spoiled, patients with such diseases should be informed about the accompanying olfactory symptoms.
Although the options for treatment of olfactory dysfunction in neurodegenerative diseases are limited, it is important to record the presence of any olfactory disorder. It has to be assumed that early diagnosis will enable earlier initiation of disease-modifying—or, in the future, perhaps neuroprotective—treatment strategies. In this way, recording of hyposmia has an important part to play.
Olfactory dysfunction accompanies many neurodegenerative diseases. Its early occurrence in IPD and AD gives it a special role in the early detection and differential diagnosis of these diseases, which may be decisive in timely initiation of treatment. Patients with olfactory dysfunction of unknown cause seem to have a two- to threefold risk of developing IPD or AD at a later point in time.
The guidelines of the German Society of Otorhinolaryngology, Head and Neck Surgery (39) thus recommend that patients with olfactory dysfunction of uncertain origin be referred to a neurologist after conclusion of the ENT work-up.
Conflict of interest statement
Prof. Hüttenbrink heads the Olfactology/Gustology Working Group of the German Society of Otorhinolaryngology, Head and Neck Surgery. The manufacturer of Sniffin’ Sticks, Burghart Messtechnik, is represented at the meetings of the working group. Research using Sniffin’ Sticks takes place in cooperation with Burghart.
Prof. Hummel has received reimbursement of congress participation fees (e.g., MDPD) and travel costs from Teva. He has received third-party funding from Teva, Takasago, Unilever, Fragrance Resources, Primavera, Bionorica, Givaudan, and Burghart (manufacturer of Sniffin’ Sticks).
Prof. Berg has received third-party funding from Teva and CIN Pharma.
Prof. Gasser has received payments from Cephalon Pharma and Merck Serono for acting as a consultant.
Dr. Hähner has received third-party funding from Teva.
Manuscript received on 29 June 2012, revised version accepted on
27 September 2012.
Translated from the original German by David Roseveare.
Prof. Dr. med. Karl-Bernd Hüttenbrink
Kerpener Str. 62, 50937 Köln, Germany
@For eReferences please refer to:
Department of Otorhinolaryngology, University Clinic Dresden: Prof. Dr. med. Hummel
Department of Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research and German Center for Neurodegenerative Diseases within the Helmholtz Association (DZNE): Prof. Dr. med. Berg, Prof. Dr. med. Gasser
Department of Neurology, University Clinic Carl Gustav Carus, Dresden University of Technology: PD Dr. med. Hähner
|1.||Stevenson RJ: An initial evaluation of the functions of human olfaction. Chem Senses 2010; 35: 3–20. CrossRef MEDLINE|
|2.||Hummel T, Nordin S: Olfactory disorders and their consequences for quality of life—a review. Acta Oto-Laryngol 2005; 125: 116–21. CrossRef MEDLINE|
|3.||Murphy C, Schubert CR, Cruickshanks KJ, Klein BE, Klein R, Nondahl DM: Prevalence of olfactory impairment in older adults. JAMA 2002; 288: 2307–12. CrossRef MEDLINE|
|4.||Vennemann MM, Hummel T, Berger K: The association between smoking and smell and taste impairment in the general population. J Neurol 2008; 255: 1121–6. CrossRef MEDLINE|
|5.||Brämerson A, Johansson L, Ek L, Nordin S, Bende M: Prevalence of olfactory dysfunction: The Skövde population-based study. Laryngoscope 2004; 114: 733–7. CrossRef MEDLINE|
|6.||Shepherd GM: Perspectives on olfactory processing, conscious perception, and orbitofrontal cortex. Ann N Y Acad Sci 2007; 1121: 87–101. CrossRef MEDLINE|
|7.||DeMaria S, Ngai J: The cell biology of smell. J Cell Biol 2010; 191: 443–52. CrossRef MEDLINE PubMed Central|
|8.||Wilson RS, Yu L, Bennett DA: Odor identification and mortality in old age. Chem Senses 2010; 36: 63–7. CrossRef MEDLINE PubMed Central|
|9.||Buck L, Axel R: A novel multigene family may encode odorant receptors: a molecular basis for odor recognition. Cell 1991; 65: 175–87. CrossRef MEDLINE|
|10.||Firestein S: How the olfactory system makes sense of scents. Nature 2001; 413: 211–8. CrossRef MEDLINE|
|11.||Gottfried JA: Smell: central nervous processing. Adv Otorhinolaryngol 2006; 63: 44–69. CrossRef MEDLINE|
|12.||Welge-Lüssen A, Hummel T: Praktisches Vorgehen bei Patienten mit Riechstörungen. In: Hummel T, Welge-Luessen A (eds.): Riech- und Schmeckstörungen. Stuttgart: Georg Thieme Verlag 2009: 3–10.|
|13.||Hummel T, Landis BN, Hüttenbrink KB: Störungen des Riechens und Schmeckens. Laryngo-Rhino-Otol 2011; 90: 44–55. CrossRef MEDLINE|
|14.||Deems DA, Doty RL, Settle RG, Moore-Gillon V, Shaman P, Mester AF, et al.: Smell and taste disorders: a study of 750 patients from the University of Pennsylvania Smell and Taste Center. Arch Otorhinolaryngol Head Neck Surg 1991; 117: 519–28. CrossRef MEDLINE|
|15.||Damm M, Temmel A, Welge-Lüssen A, Eckel HE, Kreft MP, Klussmann JP, et al.: Epidemiologie und Therapie von Riechstörungen in Deutschland, Österreich und der Schweiz. HNO 2004; 52: 112–20. CrossRef MEDLINE|
|16.||Hedner M, Larsson M, Arnold N, Zucco GM, Hummel T: Cognitive factors in odor detection, odor discrimination, and odor identification tasks. J Clin Exp Neuropsychol 2010; 30: 1–6. MEDLINE|
|17.||Doty RL, Deems D, Steller S: Olfactory dysfunction in Parkinson’s disease: A general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology 1988; 38: 1237–44. CrossRef MEDLINE|
|18.||Müller A, Mungersdorf M, Reichmann H, et al.: Olfactory function in Parkinsonian syndromes. J Clin Neurosci 2002; 9: 521–4. CrossRef MEDLINE|
|19.||Hawkes C: Olfaction in neurodegenerative disorder. Adv Otorhinolaryngol 2006; 63: 133–51. CrossRef MEDLINE|
|20.||Haehner A, Boesveldt S, Berendse HW, et al.: Prevalence of smell loss in Parkinson´s disease—a multicenter study. Parkinsonism Relat Disord 2009; 15: 490–4. CrossRef MEDLINE|
|21.||Hummel T, Kobal G, Gudziol H, Mackay-Sim A: Normative data for the „Sniffin’ Sticks“ including tests of odor identification, odor discrimination, and olfactory thresholds: an upgrade based on a group of more than 3,000 subjects. Eur Arch Otorhinolaryngol 2007; 264: 237–43. CrossRef MEDLINE|
|22.||Barz S, Hummel T, Pauli E, Majer M, Lang CJ, Kobal G: Chemosensory event-related potentials in response to trigeminal and olfactory stimulation in idiopathic Parkinson’s disease. Neurology 1997; 49: 1424–31. CrossRef MEDLINE|
|23.||Berendse HW, Roos DS, Raijmakers P, Doty R: Motor and non-motor correlates of olfactory dysfunction in Parkinson’s disease. J Neurol Sci 2011; 310: 21–4. CrossRef MEDLINE|
|24.||Ponsen MM, Stoffers D, Booij J, et al.: Idiopathic hyposmia as a preclinical sign of Parkinson’s disease. Ann Neurol 2004; 56: 173–81. CrossRef MEDLINE|
|25.||Ross GW, Petrovitch H, Abbott RD, Tanner CM, Popper J, Masaki K, Launer L, White LR: Association of olfactory dysfunction with risk for future Parkinson’s disease. Ann Neurol 2008; 63: 67–73. CrossRef MEDLINE|
|26.||Braak H, Del Tredici K, Rub U, et al.: Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 2003; 24: 97–211. CrossRef MEDLINE|
|27.||Katzenschlager R, Zijlmans J, Evans A, Watt H, et al.: Olfactory function distinguishes vascular parkinsonism from Parkinson’s disease. J Neurol Neurosurg Psychiatry 2004; 75: 1749–52. CrossRef MEDLINE PubMed Central|
|28.||Krüger S, Haehner A, Thiem C, Hummel T: Neuroleptic-induced parkinsonism is associated with olfactory dysfunction. J Neurol 2008; 255: 1574–9. CrossRef MEDLINE|
|29.||Müller A, Reuner U, Landis B, Kitzler H, Reichmann H, Hummel T: Extrapyramidal symptoms in Wilson`s disease are associated with olfactory dysfunction. Mov Disord 2006; 21: 1311–6. CrossRef MEDLINE|
|30.||Mesholam RI, Moberg PJ, Mahr RN, Doty RL: Olfaction in neurodegenerative disease: a meta-analysis of olfactory functioning in Alzheimer’s and Parkinson’s diseases. Arch Neurol 1998; 55: 84–90. CrossRef MEDLINE|
|31.||Braak H, Braak E: Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239–59. CrossRef MEDLINE|
|32.||Wilson RS, Arnold SE, Schneider JA, Boyle PA, et al.: Olfactory impairment in presymptomatic Alzheimer´s disease. Ann N Y Acad Sci 2009; 1170: 730–5. CrossRef MEDLINE PubMed Central|
|33.||Larsson M, Lundin A, Robins Wahlin TB: Olfactory functions in asymptomatic carriers of the Huntington disease mutation. J Clin Exp Neuropsychol 2006; 28: 1373–80. CrossRef MEDLINE|
|34.||Le Pichon CE, Valley MT, Polymenidou M, et al.: Olfactory behavior and physiology are disrupted in prion protein knockout mice. Nat Neurosci 2009; 12: 60–9. CrossRef MEDLINE PubMed Central|
|35.||Reden J, Müller A, Mueller C, Konstantinidis I, Landis BN, Hummel T: Recovery of olfactory function following closed head injury or infections of upper respiratory tract. Arch Otolaryngol Head Neck Surg 2006; 132: 265–9. CrossRef MEDLINE|
|36.||Pade J, Hummel T: Olfactory function following nasal surgery. Laryngoscope 2008; 118: 1260–4. CrossRef MEDLINE|
|37.||Blomqvist EH, Lundblad L, Bergstedt H, Stjarne P: Placebo-controlled, randomized, double-blind study evaluating the efficacy of fluticasone propionate nasal spray for the treatment of patients with hyposmia/anosmia. Acta Otolaryngol 2003; 123: 862–8. CrossRef MEDLINE|
|38.||Hummel T, Rissom K, Hähner A, Reden J, Weidenbecher M, Hüttenbrink KB: Effects of olfactory training in patients with olfactory loss. Laryngoscope 2009; 119: 496–9. CrossRef MEDLINE|
|39.||Deutsche Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie: Riechstörungen: Leitlinie zur Epidemiologie, Pathophysiologie, Klassifikation, Diagnose und Therapie. www.awmf.org/uploads/ tx_szleitlinien/017–050_S2_Riechstoerungen__mit_Algorithmus__ 05–2007_05–2011_01.pdf (last accessed 7 December 2012).|
|40.||Knecht M, Hüttenbrink KB, Hummel T: Störungen des Riechens und Schmeckens. Schweiz Med Wochenschr 1999; 129: 1039–46. MEDLINE|
|e1.||Delank KW: Aerodynamik im Bereich des Riechorgans. In: Wolfgang Stoll (eds.): Klinik der menschlichen Sinne, Springer Verlag, Wien 2008; 51–8.|
|e2.||Brockmann K, Gröger A, Di Santo A, Liepelt I, Schulte C, Klose U, Maetzler W, Hauser AK, Hilker R, Gomez-Mancilla B, Berg D, Gasser T: Clinical and brain imaging characteristics in leucine-rich repeat kinase 2-associated PD and asymptomatic mutation carriers. Mov Disord 2011; 26: 2335–42. MEDLINE|
|e3.||Moberg PJ, Doty RL: Olfactory function in Huntington´s disease patients and at-risk offspring. Int J Neurosci 1997; 89: 133–9. CrossRef MEDLINE|
|e4.||Jafek BW, Moran DT, Eller PM, Rowley JC, 3rd, Jafek TB: Steroid-dependent anosmia. Arch Otolaryngol Head Neck Surg 1987; 113: 547–9. MEDLINE|
|e5.||Shu CH, Lee PL, Chen KT, Lan MY: Topical corticosteroid applied with a squirt system being more effective than with nasal spray for steroid-dependent olfactory impairment. Rhinology 2012; (in press).|
|e6.||Hummel T, Jahnke U, Sommer U, Reichmann H, Müller A: Olfactory function in patients with idiopathic Parkinson’s disease: Effects of deep brain stimulation in the subthalamic nucleus. J Neural Transm 2005; 112: 669–76. CrossRef MEDLINE|
|e7.||Hähner A, Welge-Lüssen A: Riechstörungen bei neurodegenerativen Erkrankungen. HNO 2012; 7: 644–9.|
Deutsches Ärzteblatt international, 201310.3238/arztebl.2013.0345a
Neurological susceptibility to environmental exposures: pathophysiological mechanisms in neurodegeneration and multiple chemical sensitivityReviews on Environmental Health, 202110.1515/reveh-2021-0043
Olfactory Bulb D2/D3 Receptor Availability after Intrastriatal Botulinum Neurotoxin-A Injection in a Unilateral 6-OHDA Rat Model of Parkinson’s DiseaseToxins, 202210.3390/toxins14020094
Deutsches Ärzteblatt international, 201310.3238/arztebl.2013.0345b
Deutsches Ärzteblatt international, 201310.3238/arztebl.2013.0346
Deutsches Ärzteblatt international, 202110.3238/arztebl.m2021.0212
Molecular Neurobiology, 201810.1007/s12035-018-1001-4
Exploring Social Biomarkers in High-Functioning Adults with Autism and Asperger’s Versus Healthy Controls: A Cross-Sectional AnalysisJournal of Autism and Developmental Disorders, 202010.1007/s10803-020-04493-5
Molecular Neurobiology, 201910.1007/s12035-018-1341-0
Frontiers in Neurology, 202010.3389/fneur.2020.00970
Aktuel Nordisk Odontologi, 201910.18261/issn.2058-7538-2019-01-05
Brain Sciences, 202110.3390/brainsci11070952
The Olfactory System as Marker of Neurodegeneration in Aging, Neurological and Neuropsychiatric DisordersInternational Journal of Environmental Research and Public Health, 202110.3390/ijerph18136976
Frontiers in Integrative Neuroscience, 202210.3389/fnint.2022.763986
Les troubles olfactifs au cours de la sénescence et de deux principales pathologies neurodégénérativesHegel, 201610.3917/heg.062.0140
Loss of Olfactory Function—Early Indicator for Covid-19, Other Viral Infections and Neurodegenerative DisordersFrontiers in Neurology, 202010.3389/fneur.2020.569333
Frontiers in Neuroscience, 201910.3389/fnins.2019.00786